Ocelot Bio Receives FDA Orphan Drug Designation for OCE-205 for the Treatment of Ascites streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Ocelot Bio, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics to treat complications of end-stage liver disease (ESLD), today announced that the U.S. Food and Drug Administration (FDA) has granted.
(Albany, United States) As per DelveInsight’s assessment, globally, the Hepatorenal Syndrome Pipeline constitutes 3+ key companies continuously working towards developing 3+ Hepatorenal Syndrome Pipeline treatment
Katherine Vega Stultz is the CEO and president of Ocelot Bio, a clinical-stage biotech company focused on the development of therapeutics to treat complications of end-stage liver disease.